Weights cut HbA1c and blood pressure in type 2 diabetes

Cardiovascular disease is the dominant complication of type 2 diabetes, and lipid ratios such as the atherogenic index of plasma are used as summary markers of that risk. Aerobic exercise has long dominated advice for people with the condition, leaving open how much resistance training contributes on its own. That matters practically, because lifting is often more accessible and better tolerated in middle-aged and older adults than sustained aerobic work. Establishing whether it moves both lipid-based risk markers and glycaemic control would strengthen the case for including it in routine lifestyle programmes.

The authors systematically searched four databases and pooled 33 randomised controlled trials with a combined 1,396 middle-aged and older participants with type 2 diabetes. The primary outcome was the atherogenic index of plasma; secondary outcomes covered glycaemic markers including HbA1c and HOMA-IR, plus a wide range of cardiovascular risk factors such as blood pressure, body fat and aerobic capacity. Random-effects meta-analyses were used throughout, with subgroup and meta-regression analyses probing possible moderators of the effect. Sensitivity analyses re-ran the pooled estimates after excluding studies judged to be at high risk of bias.

Resistance training significantly reduced the atherogenic index of plasma, with an effect size of -0.56, and the effect was notably stronger among overweight and obese participants. Glycaemic markers also improved: HbA1c fell by 0.62% and HOMA-IR by 0.90. Systolic blood pressure dropped by 3.91 mmHg and body fat by 0.54%, while VO2max increased with an effect size of 0.53. Heterogeneity was substantial across several outcomes, but the authors report that sex, body mass index and supervision-related factors partly explained it, and that results held after excluding high-risk studies.

The analysis supports and extends the view that resistance training is not merely a strength intervention in type 2 diabetes but shifts lipid-based and glycaemic risk markers too. The consistency of the effect after removing weaker trials is reassuring, yet the pooled sample remains modest and the included studies were concentrated geographically, limiting generalisability. Differences in study design and participant demographics mean the exact magnitudes should not be treated as fixed. What the review cannot say is whether these marker changes translate into fewer cardiovascular events, or how resistance training compares head-to-head with aerobic training.

This is a reason to think resistance training belongs in the conversation about cardiometabolic risk, not just muscle and function, for people in middle age and beyond with type 2 diabetes. The improvements span lipid ratios, insulin resistance, blood pressure, body fat and aerobic capacity, which is a broader footprint than lifting is usually credited with. The larger effects in overweight and obese participants suggest who may have the most to gain, though that is a subgroup observation. The review reports averages across varied programmes and does not specify what any individual would experience.